Descriptive analysis reveals reductions in industry-sponsored drug trials post-IRA, suggesting shifts in investments.
While descriptive, this study offers early evidence of reductions in industry-sponsored new small molecule pre-approval and post-approval drug trials after IRA passage. These trends should be monitored as responses work their way through drug pipeline investment decisions.
No takes yet. Share an insight, caveat, or question.
Genia Long (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: